Navigation Links
Matrix registry probes adherence to clopidogrel at 1 year
Date:3/31/2008

CHICAGO, Ill. (March 31, 2008) A large community-based registry of patients treated with drug-eluting stents is providing important insight into how long patients with complex coronary artery disease typically stick to their doctors orders to take clopidogrel, a drug that prevents unwanted blood clots; why they stop taking the drug; and the long-term consequences of that decision.

The new data from the MATRIX Registry, a large proportion of which represents off-label use of sirolimus-eluting stents, will be reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

Long-term clopidogrel therapy appears to be a critical factor in avoiding late stent thrombosis, an uncommon but serious complication that occurs when a blood clot blocks the stent. Such clots can form a year or more after stenting and can cause a heart attack or even death.

The MATRIX Registry is particularly valuable because it provides a real-world view of a wide variety of patients, many of whom do not fit the strict profiles used in clinical trials leading to device approval by the Food and Drug Administration. Treatment of such patients with drug-eluting stents is considered off-label, but is both common in clinical practice and legal.

George Dangas, MD, PhD, an associate professor of medicine at Columbia University Medical Center and program director of interventional cardiology at New York-Presbyterian Hospital, New York City, led the new analysis of the MATRIX Registry data. A total of 1,510 patients were included in the study. They had a very different profile from patients enrolled in early clinical trials. Some 33.3 percent had previously had a heart attack, 44.4 percent had had a prior coronary intervention, 21 percent had had bypass surgery, 33.7 percent had diabetes and 27.7 percent had unstable angina.

All patients received aspirin, clopidogrel and other anti-clotting drugs during stenting. After stenting, all were prescribed aspirin 325 mg daily for one month and 81 mg indefinitely thereafter, plus clopidogrel 75 mg daily for one year, with subsequent clopidogrel prescription left up to physician discretion.

The researchers found that by six months, 10 percent of patients who were available for follow-up (133 out of 1,324) were no longer taking clopidogrel as prescribed. By one year, that number had edged up to 17.4 percent (233 out of 1,338) and by two years, to 33.2 percent (291 out of 877). However, of patients who were no longer taking clopidogrel at six months, nearly half were back on the medication at one- or two-year follow-up.

At one year, discontinuation of clopidogrel was attributed to doctors choice in 9.9 percent of patients, bleeding in 5.2 percent, surgery in 2.1 percent, rash or allergy in 1.7 percent and cost in 0.4 percent. In 39.5 percent of patients, the reason for discontinuation was unknown; 41.2 percent of patients discontinued clopidogrel simply because the recommended one-year dosing period had come to an end.

Researchers also evaluated clinical outcomes at various time points, dividing patients into those who continued taking clopidogrel and those who stopped. Patients who stopped taking clopidogrel by one year had a significantly higher risk of death when compared to those who continued taking the medication (4.8 percent vs. 1.4 percent, respectively, p=0.005); however, there was no significant difference in rates of cardiac death (1.1 percent vs. 0.2 percent, p=0.054), noncardiac death (2.7 percent vs. 1.0 percent, p=0.08) and unknown death (1.0 percent vs. 0.3 percent, p=0.16). The need for a repeat procedure to re-treat the target lesion or to reopen the target coronary artery was lower in patients who stopped taking clopidogrel (0 percent vs. 5.5 percent, p=0.001, and 0.5 percent vs. 6.1 percent, p=0.002, respectively).

Rates of stent thrombosis in the MATRIX Registry were 0.9 percent at two yearsvery low, particularly given that 86 percent of patients were treated for an off-label indication. Investigators attributed the low thrombosis rate to the highly experienced interventional cardiologists who performed stent implantation and the use of intravascular ultrasound to ensure precise stent placement in 35 percent of patients.

Dr. Dangas will present the new data from the MATRIX Registry on Monday, March 31 at 8:30 a.m. CDT in the Grand Ballroom, S100.


'/>"/>

Contact: Kathy Boyd David
pr@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

Related medicine news :

1. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. Matrixx Initiatives, Inc. to Present at the William Blair & Company Small-Cap Growth Stock Conference
3. Collagen Matrix, Inc. Receives FDA 510(k) Clearance for SynOss(TM) Synthetic Mineral Bone Graft Material
4. Matrixx Initiatives, Inc. Updates 2007/2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook
5. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2008 Financial Results
6. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
7. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
8. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
9. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
10. Rising Medical Solutions Partners With myMatrixx to Deliver Integrated Pharmacy Management Solutions
11. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... The Patient Advocacy Community of The Beryl ... 2017 Ruth Ravich Patient Advocacy Award in recognition of her extraordinary contributions ... with the award at The Beryl Institute’s annual Patient Experience Conference on ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Alive ... people who wish to overcome their mental health struggles. The Alive team uses ... LeBouthillier says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... Ramon, CA (PRWEB) , ... April 21, 2017 , ... ... might not understand the estate planning process, or where to even begin. “Now more ... unresolved if you are to properly protect yourself and your family,” said attorney Lisa ...
(Date:4/21/2017)... ... April 21, 2017 , ... During April 21-23, Super-Sod will join the ... festival offers entertainment for everyone — from the avid gardener to the landscape admirer ... high quality event held in a grand venue, and we are certainly looking forward ...
(Date:4/21/2017)... ... April 21, 2017 , ... MiracleFeet announced today ... years to help end the disability caused by untreated clubfoot in low-income countries. ... Global Clubfoot Initiative to end disability caused by clubfoot worldwide. , ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  New research provides evidence ... advanced Parkinson,s, according to a study released today that will ... Annual Meeting in Boston , April ... to the treatment of Parkinson,s disease, the oral drug levodopa ... life and longevity. But as the disease progresses, the effects ...
(Date:4/18/2017)... , April 18, 2017 Viverae ® ... to announce the integration of IBM ® Watson ... to deliver targeted communications for a personalized experience. Through ... actions on their health in real time. The enhanced ... matter most to members, wherever they are in their ...
(Date:4/18/2017)... -- Research and Markets has announced the addition ... Equipment and Radiopharmaceuticals Market, Forecast to 2023" report to ... This ... well as growth in the number of unit shipments over ... participants that design and manufacture molecular imaging equipment. ...
Breaking Medicine Technology: